Prostate Cancer

Use of focal therapy was shown to prolong the duration of active surveillance.

The trial has enrolled 201 patients with localized prostate cancer to date.

Initial study results may be available as soon as the first half of 2026.

"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

More than 80% of patients in both groups had a full recovery of testosterone.

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

We preview several noteworthy P2 presentations in the urologic oncology space.

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.

"We should not be preemptively reducing the dose for all our patients, because half of the patients will never develop grade 3/4 anemia," says Neeraj Agarwal, MD, FASCO.

"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.

A lookahead of the notable FDA decisions and conferences slated for Q2 2025.

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.

The company plans to initiate the phase 2 monotherapy trial by mid-year.

"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.

The approval is supported by positive data from the phase 3 PSMAfore trial.